Sermorelin Before and After
What published human studies measured, over what period, and what they did not show.
Published human studies of sermorelin and a closely related GHRH(1-29) peptide were small and short, lasting 2 to 16 weeks in adults. They mostly measured growth hormone and IGF-1 levels; body-composition and sleep findings were mixed or unchanged. None studied today’s compounded product. Results vary, and a licensed provider sets expectations for your situation.
Compounded sermorelin is not FDA-approved; sermorelin was approved as Geref in 1997 and discontinued in 2008.
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
What published human studies measured
There are no large, long-term trials of sermorelin in adults. The human studies below are the ones most often referenced. Each was small, and each used a 1990s research or branded preparation, not the compounded sermorelin prescribed today.
| Study | Who took part | Dose and period | What changed | What did not change |
|---|---|---|---|---|
| Corpas et al., 1992 | 10 healthy men, average age 68 (9 young men measured for comparison) | GHRH(1-29) under the skin twice daily, 0.5 mg and 1 mg, 14 days each in random order | At 1 mg, 24-hour growth hormone and IGF-1 rose, to levels not significantly different from the young men | At 0.5 mg, no significant change; fasting glucose, blood pressure and routine blood tests unchanged |
| Vittone et al., 1997 | 11 healthy men aged 64 to 76 with low IGF-1 | 2 mg under the skin once nightly for 6 weeks; open study, no placebo group | Night-time growth hormone release rose | IGF-1 did not change; body weight, BMI, waist-to-hip ratio and DEXA body-composition measures did not change |
| Khorram et al., 1997 | 10 women and 9 men aged 55 to 71 | [Nle27]GHRH(1-29), a modified form of the same peptide, nightly for 16 weeks after 4 weeks of placebo; single-blind | IGF-1 rose within 2 weeks; skin thickness rose in both sexes; lean body mass, insulin sensitivity and well-being scores rose in men, not in women | Sleep quality, body weight and bone density did not change; IGF-1 drifted back toward baseline by week 16 |
| Prakash & Goa, 1999 (review) | Children with idiopathic growth hormone deficiency, the use Geref was approved for | 30 µg/kg under the skin once daily at bedtime, for 12 months and longer | Growth rate (height velocity) rose and stayed higher over 12 months | Gains were smaller than with daily somatropin; effect on final adult height was not known |
Doses are shown as published, for context. They are not a dosing guide; a licensed provider sets any dose.
What studies report by week and month
- Within 2 weeks: studies report a rise in IGF-1 at the higher twice-daily dose (Corpas) and with nightly doses of the modified analog (Khorram). The lower twice-daily dose in Corpas did not produce a significant change.
- At 6 weeks: with one nightly 2 mg dose, the study reports higher night-time growth hormone but no change in IGF-1 or in measured body composition (Vittone).
- Weeks 12 to 16: in the 16-week analog study, IGF-1 stayed raised through week 12 and drifted back toward baseline by week 16; sleep quality did not change (Khorram).
- At 12 months: in children with growth hormone deficiency, studies report a sustained rise in growth rate (Prakash & Goa). That is a pediatric use and does not describe adults.
These are group averages from small studies. They describe what researchers measured, not what any one person notices or experiences.
What these studies did not show
- None tested today’s compounded sermorelin. The compounded product has not been studied as a finished product.
- None was large or long: each adult study had 19 or fewer participants and lasted 16 weeks or less.
- None reported a change in body weight. In the two adult studies that measured it, weight did not change.
- None measured sleep as a main outcome. The one study that asked about sleep quality found no change.
- A change in a lab value such as IGF-1 is not the same as a change in how a person feels or functions.
- No REMEVi patient results are shown on this page. REMEVi does not publish before-and-after photos or patient numbers.
Talk to a licensed provider
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
Does sermorelin work?
It depends on what “work” means. Small published studies show sermorelin and a related GHRH(1-29) peptide can raise growth hormone release, and at some doses IGF-1, over weeks. They did not consistently show changes in body weight, body composition or sleep, and none studied today’s compounded product. A licensed provider can explain what to expect.
How long does sermorelin take to work?
Published adult studies measured changes over 2 to 16 weeks. IGF-1 rose within 2 weeks in two studies at certain doses, while a 6-week nightly study found no IGF-1 change. There is no standard timeline for how a person feels. Your licensed provider sets realistic expectations for your situation and checks in with you over time.
Why results vary
Results vary from person to person. A licensed provider sets the dose and schedule individually, and age, sleep, nutrition, activity, other health conditions and other medicines all affect what gets measured. That is why someone else’s before-and-after tells you little about your own course.
Sermorelin at REMEVi is $229 every 4 weeks (28 days), month-to-month, including the clinical evaluation, the prescribed medication if approved, supplies and shipping. A licensed provider reviews your health history first and decides whether sermorelin fits.
Sermorelin at REMEVi · Sermorelin cost · Is sermorelin FDA-approved?
More questions
Does REMEVi publish sermorelin before-and-after photos?
No. REMEVi does not publish patient photos, results or numbers for sermorelin. Photos and testimonials online are not controlled evidence, cannot be verified, and do not account for diet, training, sleep, age or other medicines.
Were these studies done on compounded sermorelin?
No. They used research or branded GHRH(1-29) preparations from the 1990s, and one used a modified analog. Compounded sermorelin is not FDA-approved and has not been studied as a finished product, so these studies describe the molecule, not a specific pharmacy’s preparation.
What should I ask a provider before starting?
Ask what a realistic course looks like for you, which labs or symptoms they will check, how often they will follow up, and when they would reassess or stop. A licensed provider reviews your health history before anything is prescribed.
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
Sources
- Corpas et al., J Clin Endocrinol Metab 1992 — Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men (read November 2, 2026)
- Vittone et al., Metabolism 1997 — Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (read November 2, 2026)
- Khorram et al., J Clin Endocrinol Metab 1997 — Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women (read November 2, 2026)
- Prakash & Goa, BioDrugs 1999 — Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (read November 2, 2026)
- FDA — Orphan Drug Designations and Approvals: sermorelin acetate (Geref) (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·